Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. (SHA:688076)

SHA:688076 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	1,834	1,625	1,033	648.03	641.71	564.99
Other Revenue	-	-	0.82	3.26	2.16	1.89
Revenue	1,834	1,625	1,034	651.29	643.87	566.87
Revenue Growth (YoY)	55.28%	57.21%	58.69%	1.15%	13.58%	52.58%
Cost of Revenue	1,220	525.06	444.27	307.94	306.3	249.55
Gross Profit	614.86	1,100	589.28	343.36	337.57	317.32
Selling, General & Admin	35.14	352.69	268.23	186.98	150.49	120
Research & Development	12.23	227.45	124.89	69.47	63.09	60.53
Other Operating Expenses	3.63	-5.56	0.02	9.25	5.24	3.65
Operating Expenses	44.48	574.58	398.25	271.58	220.47	185.87
Operating Income	570.38	525.16	191.04	71.78	117.1	131.45
Interest Expense	-6.55	-	-16.09	-9.26	-6.12	-11.63
Interest & Investment Income	1.12	1.07	9.11	28.54	8.38	7.16
Currency Exchange Gain (Loss)	-	-	-1.38	1.03	-1.58	-7.73
Other Non Operating Income (Expenses)	-11.03	-49.01	-0.47	-0.3	-0	-1.12
EBT Excluding Unusual Items	553.93	477.23	182.22	91.79	117.78	118.14
Impairment of Goodwill	-	-	-	-	-1.28	-
Gain (Loss) on Sale of Investments	-	-2.79	0.26	-1.96	0.13	-
Gain (Loss) on Sale of Assets	-0.26	0.5	-15.06	18.44	-0.97	-4.12
Asset Writedown	-12.76	-36.43	-	-	-	-
Other Unusual Items	0.83	-	5.71	14.9	10.07	32.55
Pretax Income	541.73	438.5	173.13	123.16	125.73	146.56
Income Tax Expense	57.7	38.69	7.67	0.39	16.92	26.53
Earnings From Continuing Operations	484.03	399.82	165.45	122.77	108.81	120.03
Minority Interest in Earnings	2.98	4.57	-2.52	6.34	6.58	3.41
Net Income	487.01	404.39	162.94	129.11	115.39	123.44
Net Income to Common	487.01	404.39	162.94	129.11	115.39	123.44
Net Income Growth	133.86%	148.19%	26.20%	11.89%	-6.52%	153.94%
Shares Outstanding (Basic)	217	215	214	212	192	160
Shares Outstanding (Diluted)	217	220	214	212	192	160
Shares Change (YoY)	0.05%	2.51%	1.29%	10.05%	19.96%	-1.06%
EPS (Basic)	2.24	1.88	0.76	0.61	0.60	0.77
EPS (Diluted)	2.24	1.84	0.76	0.61	0.60	0.77
EPS Growth	133.73%	142.10%	24.59%	1.67%	-22.08%	156.67%
Free Cash Flow	-	-690.01	-310.43	-409.07	-52.61	30.1
Free Cash Flow Per Share	-	-3.14	-1.45	-1.93	-0.27	0.19
Dividend Per Share	-	-	0.400	0.200	0.150	-
Dividend Growth	-	-	100.00%	33.33%	-	-
Gross Margin	33.52%	67.69%	57.02%	52.72%	52.43%	55.98%
Operating Margin	31.09%	32.32%	18.48%	11.02%	18.19%	23.19%
Profit Margin	26.55%	24.89%	15.77%	19.82%	17.92%	21.78%
Free Cash Flow Margin	-	-42.47%	-30.04%	-62.81%	-8.17%	5.31%
EBITDA	-	727.77	322.43	170.52	198.73	202.16
EBITDA Margin	-	44.79%	31.20%	26.18%	30.87%	35.66%
D&A For EBITDA	-	202.61	131.39	98.75	81.63	70.71
EBIT	570.38	525.16	191.04	71.78	117.1	131.45
EBIT Margin	31.09%	32.32%	18.48%	11.02%	18.19%	23.19%
Effective Tax Rate	10.65%	8.82%	4.43%	0.32%	13.46%	18.10%
Revenue as Reported	209.78	-	1,034	651.29	643.87	566.87

Source: S&P Global Market Intelligence. Standard template. Financial Sources.